January 2007 in “Inpharma Weekly” Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
64 citations
,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
January 2012 in “Medical Journal of Babylon” March 2005 in “The Nurse Practitioner” June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
1 citations
,
July 2024 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is effective and safe for treating frontal fibrosing alopecia.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
14 citations
,
January 2022 in “Evidence-based Complementary and Alternative Medicine” Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
February 2024 in “The Journal of Sexual Medicine” 5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
April 2007 in “The Journal of Urology” Finasteride reduces bleeding risk during prostate surgery.
January 2005 in “Urology” Alfuzosin reduces short-term surgery need after catheter removal, but long-term benefits are unclear; combination therapy may help prevent urinary issues.
September 2004 in “Inpharma Weekly” Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
January 2023 in “Springer eBooks” 26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
125 citations
,
January 1999 in “Drugs” Finasteride effectively treats baldness but may cause sexual side effects.
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
65 citations
,
October 2008 in “Journal of Neuroendocrinology”